Literature DB >> 11705995

The globular domain of the proalpha 1(I) N-propeptide is not required for secretion, processing by procollagen N-proteinase, or fibrillogenesis of type I collagen in mice.

Paul Bornstein1, Vanessa Walsh, Jennifer Tullis, Emily Stainbrook, John F Bateman, Sheriar G Hormuzdi.   

Abstract

The globular domain in the NH(2)-terminal propeptide (N-propeptide) of the proalpha1(I) chain is largely encoded by exon 2 of the Col1a1 gene and has been implicated in a number of processes that are involved in the biogenesis, maturation, and function of type I collagen. These include intracellular chain association, transcellular transport and secretion, proteolytic processing of the precursor, feedback regulation of synthesis, and control of fibrillogenesis. However, none of these proposed functions has been firmly established. To evaluate the function of this procollagen domain we have used a targeted mutagenesis approach to generate mice that lack exon 2 in the Col1a1 gene. Mouse lines were established on both a mixed 129 OlaHsd/Sv and C57BL/6 background and a pure 129 OlaHsd/Sv background. Adult mice on the mixed background are normal in appearance and are fertile. To the extent that they have been studied, procollagen synthesis, secretion, and proteolytic processing are normal in these mice, and collagen fibrillogenesis is only slightly altered. However, breeding of heterozygous mutant mice on the 129 background generated homozygous mutants at only 64% of the expected frequency. These findings suggest that although the N-propeptide is not essential for collagen biogenesis in mice it may play some essential role during embryonic development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11705995     DOI: 10.1074/jbc.M106181200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Prospects and limitations of the rational engineering of fibrillar collagens.

Authors:  Ireneusz Majsterek; Erin McAdams; Eijiro Adachi; Shirish T Dhume; Andrzej Fertala
Journal:  Protein Sci       Date:  2003-09       Impact factor: 6.725

2.  Disruption of the developmentally-regulated Col2a1 pre-mRNA alternative splicing switch in a transgenic knock-in mouse model.

Authors:  Renate Lewis; Soumya Ravindran; Louisa Wirthlin; Geoffrey Traeger; Russell J Fernandes; Audrey McAlinden
Journal:  Matrix Biol       Date:  2012-01-09       Impact factor: 11.583

3.  The NH2-terminal propeptide of type I procollagen acts intracellularly to modulate cell function.

Authors:  Anush Oganesian; Sandra Au; Jeremy A Horst; Lars C Holzhausen; Athena J Macy; James M Pace; Paul Bornstein
Journal:  J Biol Chem       Date:  2006-10-03       Impact factor: 5.157

Review 4.  Recent advances in the use of serological bone formation markers to monitor callus development and fracture healing.

Authors:  Marlon O Coulibaly; Debra L Sietsema; Travis A Burgers; Jim Mason; Bart O Williams; Clifford B Jones
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2010       Impact factor: 1.807

5.  Expression in SPARC-null mice of collagen type I lacking the globular domain of the α1(I) N-propeptide results in abdominal hernias and loss of dermal collagen.

Authors:  Lauren Card; Nikki Henderson; Yuhua Zhang; Paul Bornstein; Amy D Bradshaw
Journal:  Matrix Biol       Date:  2010-08-11       Impact factor: 11.583

Review 6.  Alternative splicing of type II procollagen: IIB or not IIB?

Authors:  Audrey McAlinden
Journal:  Connect Tissue Res       Date:  2014-04-18       Impact factor: 3.417

7.  Giantin is required for intracellular N-terminal processing of type I procollagen.

Authors:  Nicola L Stevenson; Dylan J M Bergen; Yinhui Lu; M Esther Prada-Sanchez; Karl E Kadler; Chrissy L Hammond; David J Stephens
Journal:  J Cell Biol       Date:  2021-05-04       Impact factor: 10.539

8.  SPARC and the N-propeptide of collagen I influence fibroblast proliferation and collagen assembly in the periodontal ligament.

Authors:  Emilie Moore Rosset; Jessica Trombetta-eSilva; Glenn Hepfer; Hai Yao; Amy Dodd Bradshaw
Journal:  PLoS One       Date:  2017-02-28       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.